346 related articles for article (PubMed ID: 27514012)
1. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
[TBL] [Abstract][Full Text] [Related]
2. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
[TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
5.
Garin E; Rolland Y; Edeline J
Semin Nucl Med; 2019 May; 49(3):218-226. PubMed ID: 30954188
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
7. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
Garin E; Rolland Y; Laffont S; Edeline J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
[TBL] [Abstract][Full Text] [Related]
10. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
12. Radioembolization with
Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
14. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
15.
Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
[TBL] [Abstract][Full Text] [Related]
17. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
[TBL] [Abstract][Full Text] [Related]
18. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
Palard X; Edeline J; Rolland Y; Le Sourd S; Pracht M; Laffont S; Lenoir L; Boudjema K; Ugen T; Brun V; Mesbah H; Haumont LA; Loyer P; Garin E
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
[TBL] [Abstract][Full Text] [Related]
20. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
